Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064439 · ClinicalTrials.gov registry record · Phase 3
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,365
- Enrollment target
NCT02064439: Completed Phase 3 study, sponsored by Bayer.
NCT02064439 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 3,365 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (336% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02064439, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,365 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial
Primary Outcome
The primary efficacy outcomes (i.e., recurrent venous thromboembolism \[VTE\] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism \[PE\] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the firs
Interventions
- DRUG ASA
- DRUG BAY 59-7939
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,365 participants |
| Start Date | 2014-03-05 |
| Est. Completion | 2016-11-04 |
| Phase | Phase 3 |
What the finished NCT02064439 record still lists
NCT02064439 is an interventional study that assigns participants to a tested intervention. Its 3,365 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (336% higher).
The record links to 0 conditions, and to 2 interventions - of which ASA is the first listed.
NCT02064439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02064439 about?
NCT02064439 is a clinical study titled "Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)". This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial
What is the current status of trial NCT02064439?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,365 participants. The study started on 2014-03-05. Estimated completion is 2016-11-04.
What interventions are being tested in trial NCT02064439?
The interventions under investigation include: ASA (DRUG), BAY 59-7939 (DRUG).
Who is sponsoring clinical trial NCT02064439?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02064439's enrollment target sits among peer trials
3,365 72nd of 2000 higher than 1,929 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI